ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011

SAN DIEGO—(BUSINESS WIRE)—Dec. 7, 2011—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the Oppenheimer 22^ndAnnual Healthcare Conference on Wednesday, December 14, 2011, at 11:05a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through December 28, 2011.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA has four product candidates inclinical development including pimavanserin, which is in Phase IIIdevelopment as a potential first-in-class treatment for Parkinson’sdisease psychosis. ACADIA also has a product candidate in Phase IIdevelopment for chronic pain and a product candidate in Phase Idevelopment for glaucoma, both in collaboration with Allergan, Inc., andAM-831 in Phase I development for schizophrenia in collaboration withMeiji Seika Pharma Co., Ltd. All of the product candidates in ACADIA’spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA’sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2010as well as other subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
858-558-2871